Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Coegin Pharma

4,29 SEK

+0,23 %

Mindre end 1K følgere

COEGIN

Nordic SME

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+0,23 %
-3,38 %
-13,86 %
-34,40 %
+26,55 %
+1,66 %
-62,86 %
-75,59 %
-86,51 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Læs mere
Markedsværdi
106,72 mio. SEK
Aktieomsætning
39,31 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
26.2
2026

Årsrapport '25

21.5
2026

Delårsrapport Q1'26

21.5
2026

Generalforsamling '26

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse2.1.2026, 08.30

Coegin Pharma provides an operational and strategic update

Coegin Pharma
Pressemeddelelse22.12.2025, 12.30

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Coegin Pharma
Pressemeddelelse19.12.2025, 08.25

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Coegin Pharma

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse12.12.2025, 10.50

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma
Selskabsmeddelelse27.11.2025, 08.45

Coegin Pharma's Nomination Committee appointed for the 2026 Annual General Meeting

Coegin Pharma
Selskabsmeddelelse20.11.2025, 13.50

Coegin Pharma AB (publ) publishes its quarterly report for the third quarter of 2025

Coegin Pharma
Pressemeddelelse14.11.2025, 13.42

First Follicopeptide® powered product available for consumer pre-orders November 16 - a historic milestone for Coegin Pharma

Coegin Pharma
Pressemeddelelse6.11.2025, 13.45

Coegin introduces new tailor-made Follicopeptide complementary product - launching early 2026

Coegin Pharma
Selskabsmeddelelse17.10.2025, 15.05

Coegin Pharma enters collaboration with Hårklinikken - expands Follicopeptide® commercialization with a world renowned hair clinic brand

Coegin Pharma
Pressemeddelelse13.10.2025, 08.02

Coegin Pharma establishes own agile production facility in Denmark - ensuring control, scalability, and cost efficiency for next phase of growth

Coegin Pharma
Selskabsmeddelelse17.9.2025, 12.30

Coegin Pharma enters collaboration with Polish distributor Mercapharm - expands Follicopeptide® commercialisation to Poland

Coegin Pharma
Selskabsmeddelelse10.9.2025, 13.00

Coegin Pharma enters collaboration with Swedish retailer Gents - kicks off next phase of Follicopeptide commercialisation

Coegin Pharma
Selskabsmeddelelse21.8.2025, 12.30

Coegin Pharma AB (publ) publishes its Interim Report for the second quarter of 2025

Coegin Pharma
Pressemeddelelse20.8.2025, 06.30

Coegin Pharma provides status update ahead of the upcoming commercialisation of its first Follicopeptide-based hair growth product

Coegin Pharma
Selskabsmeddelelse12.8.2025, 12.45

Coegin Pharma changes language for company communication to English

Coegin Pharma
Pressemeddelelse2.7.2025, 06.30

Coegin Pharma has reduced product cost by 80 percent - moving closer to the launch of Follicopeptide

Coegin Pharma
Selskabsmeddelelse22.5.2025, 11.30

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Selskabsmeddelelse22.5.2025, 06.35

Coegin Pharma AB publishes its quarterly report for the first quarter of 2025

Coegin Pharma
Selskabsmeddelelse29.4.2025, 10.45

Coegin Pharma AB publishes Annual Report for the financial year 2024

Coegin Pharma
Selskabsmeddelelse16.4.2025, 11.30

Notice of Annual General Meeting in Coegin Pharma AB (publ)

Coegin Pharma
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.